Myotonic dystrophy is a neuromuscular disease of RNA toxicity. The disease gene DMPK harbors expanded CTG trinucleotide repeats on its 3′-UTR. The transcripts of this mutant DMPK led to misregulation of RNA-binding proteins including MBNL1 and Celf1. In myoblasts, CUG-expansion impaired terminal differentiation. In this study, we formally tested how the abundance of Celf1 regulates normal myocyte differentiation, and how Celf1 expression level mediates CUG-expansion RNA toxicity-triggered impairment of myocyte differentiation. As the results, overexpression of Celf1 largely recapitulated the defects of myocytes with CUG-expansion, by increasing myocyte cycling. Knockdown of endogenous Celf1 level led to precocious myotube formation, supporting a negative connection between Celf1 abundance and myocyte terminal differentiation. Finally, knockdown of Celf1 in myocyte with CUG-expansion led to partial rescue, by promoting cell cycle exit. Our results suggest that Celf1 plays a distinctive and negative role in terminal myocyte differentiation, which partially contribute to DM1 RNA toxicity. Targeting Celf1 may be a valid strategy in correcting DM1 muscle phenotypes, especially for congenital cases.
Introduction
Myotonic muscular dystrophy is a common multi-system disorder that affects the skeletal and cardiac muscles. It has two types with DM1 being the more frequent and severe. In DM1, the disease gene DMPK1 harbors an expansion of CUG triplet repeats on its 3′-UTR [1, 2] . Consequently, RNA-binding factors (MBNL1 and Celf1) which bind to the CUG repeats are misregulated. Both MBNL1 and Celf1 contribute to DM1 pathogenesis. MBNL1 is sequestered by the expanded CUG repeats, resulting in a loss of function [3] , and aberrant alternative splicing of its targets [4] . MBNL1 knockout mice developed some of the characteristics of DM1, in particular, misregulated mRNA splicing [5] . CUG-expansion augments Celf1, which regulates alternative splicing, RNA stability and translation [6, 7] . Heart-specific overexpression of Celf1 caused histopathological and echocardiographic abnormalities, and aberrant alternative splicing [8] . In the skeletal muscles, overexpression of Celf1 also reproduced DM1-like features, which were associated with Celf1-responsive alternative splicing or aberrant stability of Celf1 targets p21 and MEF2A [9] . While knockout of MBNL1 did not have apparent effects, overexpression of Celf1 in either the heart or skeletal muscles reproduced DM1-like muscle wasting phenotypes [8, [10] [11] [12] [13] [14] .
Most DM1 cases are progressive and affect adults. However, congenital cases are more severe and often lead to early lethality. The copy number of CUG triplet repeats on DMPK 3′-UTR is directly related to age of onset and severity, with high copy number associated with congenital DM1 and lethality. It was shown by serial deletions that a region on the DMPK 3′-UTR excluding the CUG-expansion was responsible for defective terminal myocyte differentiation [15, 16] . However, other evidence supports that CUG-expansion was the culprit [17, 18] , through compromising the expression of a crucial myogenic factor MyoD, which may explain the lack of muscle regeneration in severe DM1 cases [17] . Celf1 expression levels are directly linked to the CUG repeat copy number in congenital DMs. When expressed as a transgene, Celf1 inhibited myogenesis in mouse [9] . However, the role of Celf1 in myoblast differentiation toward myotube is complex in current literature. It was reported that different trans-regulating factors occupy the promoter of Celf1 at different differentiation stages: while they are E12, CBP and p300 in myoblasts, the combination changes to myogenin, E12 and p300 in myotubes, suggesting an active role of Celf1 in myotube formation [19] . Also, interactions of CUGBP1 with eIF2 are reduced in DM1 differentiating myoblast cells, and exogenous cyclin D3 rescues the DM1 myoblast differentiation defects by promoting the CUGBP1-eIF2 complex [20, 21] . Furthermore, overexpression of CUGBP1 induced the expression of Mef2A and p21 during myocyte differentiation, but such a pattern does not agree with the defective myocyte differentiation [9] .
Here, we set to study how the abundance of Celf1 regulates normal myocyte differentiation, and how Celf1 expression level mediates CUG-expansion RNA toxicity-triggered impairment of it. This work may provide insight for using Celf1 as a target in promoting normal muscle development and correcting DM1-related defective muscle differentiation.
Results

3′-UTR CUG-expansion leads to accelerated cell cycling in myoblasts and impaired differentiation
Although DMPK mutation is responsible for DM1, the detailed mechanism of how DMPK mutation causes DM1 is not entirely clear. Recent evidence supports that the 3′-UTR CUG-expansion plays a central role in DM1 pathogenesis. At organism level, also in myoblasts, the CUG-expansion has been shown to inhibit terminal myocyte differentiation. Independent groups demonstrated that myotube formation was severely impaired in C2C12 cells transfected with DMPK or reporter transgene-carried 3′-UTR CTG expansions. To set up a platform for the rest of this study, also to test the cell cycle changes of proliferating and differentiating myoblasts harboring 3′-UTR CTG expansions, we transfected C2C12 myoblasts with GFP-CUG5 or GFP-CUG200, which differ only in CUG repeat number. Cells were selected for G418 resistance, and survival clones were pooled. Using FACS, we further enriched the GFP-positive cells and confirmed that GFP fluorescent signal was present in more than 97% of cells in both groups (Supplemental Fig. S1 ). The myoblasts were differentiated in a standard protocol with serum starvation and insulin supplements. After 6 days, myotubes were evidently formed in GFP-CUG5-transfected cells, as visualized by alpha myosin heavy chain staining (MF20). In contrast, they were rarely detected in GFP-CUG200 cultures (Fig. 1A) . Quantification of three independent experiments showed that fusion indices in GFP-CUG5 cultures often reached 38.9 ± 8.7%, but they were only 2.2 ± 0.8% in GFP-CUG200 cultures. Similarly, myotube areas were 40.2 ± 12.0% in GFP-CUG5 cultures but only 3.3 ± 0.8% in GFP-CUG200 cultures (Fig. 1B) . These results agree with previous reports on the effect of CUG-expansion RNA toxicity in myocyte differentiation.
We analyzed expression of a number of muscle differentiation regulators. Compared to CUG5, CUG200 significantly increased the expression of Celf1 mRNA in both proliferating myoblasts and at the beginning of differentiation, agreeing with the frequent observation that Celf1 upregulation is associated with CUG-expansion in DM1 (Fig. 1C) . Celf1 protein level was elevated accordingly (Fig. 1D) . Through the course of differentiation, Celf1 mRNA dropped rapidly, which differs from previous report of Celf1 upregulation during terminal myocyte differentiation. The minor difference in media composition (the presence of dexamethasone in previous studies) may have contributed to the discrepancy, dropping of Celf1 level during myoblast differentiation, however, agrees more with its detrimental effect in myotube formation. CUG200 inhibited myoD expression in both proliferating and differentiating cells, as previously reported [17] . MyoG and Mef2c expression was inhibited by CUG200, consistent with defective differentiation (Fig. 1C) .
We next analyzed the impact of CUG-expansion on cell cycle control. Because cell fusion creates heterogeneity in cell size, and at late stages of myotube fusion the size of cells is not compatible with FACS, we limit the analyses to early stages of culture. In proliferating undifferentiated myoblasts, CUG200 led to significantly less cells in G1 phase, suggesting increased cell cycling (Fig. 1E ). RNA toxicity is not known to be involved in cell cycle regulation in DM, we hence set to study the mechanism of it.
Overexpression of Celf1 inhibits myoblast cell cycle exit and impairs differentiation
Compared to the established role of mutant DMPK 3′-UTR in inhibiting myocyte differentiation, the role of Celf1 is unclear. In particular, Celf1 induction was reported to be part of the differentiation program. To reconcile such discrepancies, we constructed a pMSCVbased retroviral vector encoding a Flag-tagged Celf1, and used it to transduce C2C12. Puromycin-resistant clones were pooled for differentiation studies. Flag-tagged Celf1 was only present in the pMSCV-Celf1Flag transduced cells, which also showed an overall upregulation of Celf1 protein ( Fig. 2A ). During differentiation, Celf1 overexpression led to a significant drop of myotube formation. MF20 positive staining was sporadic in Celf1-overexpressing cultures (Fig. 2B) . Consistently, quantification of myotube formation by fusion indices (5.2 ± 2.0% in Celf1Flag vs. 34.9 ± 11.7% in controls) and myotube areas (5.4 ± 3.0% in Celf1Flag vs. 29.8 ± 12.7% in controls) suggests that overexpression of Celf1 severely impair terminal myocyte differentiation (Fig. 2C) . By analyzing gene expression over the course of differentiation, we found that Celf1 overexpression led to an increase of MyoD expression in undifferentiated myoblasts. This result is in line with previous reports where Celf1 and
MyoD both drive p21 expression at the initiation step of differentiation [9] . Despite increased MyoD expression, MyoG and Mef2c were both inhibited, agreeing with defective myotube formation ( Fig. 2D) . At single cell level, immunostaining of Flag and alpha myosin heavy chain showed that the exogenous Celf1 was chiefly located in the nucleus, and such nuclei did not participate in myotube formation (Fig. 3A) . Thus, upregulation of Celf1 in the nucleus is not compatible with nascent myotubes.
FACS cell cycle analyses showed that Celf1 overexpression led to defective cell cycle exit during differentiation. 30.7% Celf1-overexpressing myoblasts were in G1 phase at undifferentiated state, considerably lower than control myoblasts in G1 (43.6%, Fig. 3B ). This result largely recapitulated the cell cycle defect caused by RNA toxicity (Fig. 1E ). Celf1 overexpression prevented exit from cell cycling at the initiation stage of differentiation: there were 53.5% G1 cells in control myoblasts, vs. 34.9% in Celf1-overexpressing myoblasts. These data suggest that upregulation of Celf1 may be responsible for cell cycle exit defect in CUG-expansion RNA toxicity.
Aberrant alternative splicing events are one of the chief characteristics of DM. Here we studied if overexpression of Celf1 led to such changes in myoblasts. Aberrant inclusion of exon 11 of Zasp, exon 7 of MBNL1, exons Zr4 and Zr5 of Z-TTN, exon Mex5 of M-TTN, and exon 11 of Bin1, among a large number of aberrant alternative splicing events, was well established to be associated with DM1 [22, 23] . By analyzing these exons, we found that alternative splicing events were dynamic during myoblast differentiation. For example, exon 11 of Zasp and exon Zr4 and Zr5 of Z-TTN showed increased inclusion along the course of myotube formation. Overexpression of Celf1 did not change the patterns of such dynamic changes of the gene/exons under study (Supplemental Fig. S2 ). These data suggest that aberrant alternative splicing does not mediate the inhibiting role of Celf1 in myoblast differentiation.
Knockdown of Celf1 promotes precocious myocyte differentiation
During embryogenesis and in adult tissues, Celf1 and other Celf family members are abundantly expressed in neuroectoderm-derived properties and less in the muscular system. Despite the established role in DM1, the requirement of Celf1 in myocyte differentiation is not established. Thus, we used lentivirus-carried shRNA to knockdown Celf1 in C2C12 myoblasts. Puromycin (1 μg/ml) resistant clones transduced with the lentiviral vectors were pooled for further experiments. Effective reduction (~80%) of Celf1 was confirmed by western blot (Fig. 4A) .
Upon differentiation, myotube formation was accelerated in Celf1 knockdown cells. In our routine C2C12 differentiation experiments, appearance of cell fusion starts after 3 days of induction in small numbers, which prevailed in Celf1 knockdown cells (observation not shown). To determine if Celf1 knockdown leads to precocious myocyte differentiation, we collected samples for immunostaining at day 6, two days earlier than in other experiments. Celf1 knockdown resulted in significantly increased myotube formation over control cultures (Fig. 4B) . Fusion indices and myotube areas were 45.0 ± 7.1% and 38.6 ± 7.2%, respectively, vs. 22.0 ± 1.9% and 16.1 ± 2.6% in control cells (Fig. 4C) . By realtime RT-PCR, we found that knockdown of Celf1 persisted throughout the gradual dropping course of its expression pattern. The expression of MyoD, MyoG and Mef2c showed significant increases in Celf1 shRNA cultures, supporting increased myocyte differentiation (Fig. 4D ).
Knockdown of Celf1 partially rescues CUG-expansion induced myocyte differentiation defects
Next, we asked if Celf1 contributes to the RNA toxicity effect in inhibiting myocyte differentiation. Into the C2C12 cells stably transfected with GFP-CUG200, we delivered Celf1 shRNA by lentiviral vectors. Double resistant cells (G418 and puromycin) were selected and pooled for differentiation studies. In the presence of Celf1 shRNA, the level of endogenous Celf1 protein was greatly reduced when compared to cells stably expressing a scrambled shRNA (Fig. 5A ).
The presence of Celf1 shRNA led to improved myocyte differentiation in GFP-CUG200 cells. Compared to few multinucleate myotubes in GFP-CUG200 cells expressing a scrambled shRNA, multinucleate myotubes were evident in cells expressing Celf1 shRNA (Fig. 5B) . Fusion indices were improved from 2.3 ± 1.4% to 17.6 ± 1.1% by Celf1 shRNA. Consistently, myotube areas were improved from 4.7 ± 3.1% to 12.7 ± 2.4% (Fig. 5C ). Celf1 knockdown in GFP-CUG200 cells did not completely restore the differentiation to what's seen in wildtype myoblasts (compare Figs. 5B, C to 1A, B), suggesting that additional downstream factors were involved in CUG-expansion-induced RNA toxicity on myogenesis. Realtime RT-PCR assays of myoD, MyoG and Mef2c also support that Celf1 shRNA partially rescued the differentiation defects in CUGexpansion cells (Fig. 5E) .
FACS cell cycle analyses showed that Celf1 shRNA corrected the aberrantly increased cell cycling in CUG200 cells. There were 43.3% of G1 cells in Celf1 shRNA/CUG200 cells, considerably greater than 31.5% G1 in scrambled shRNA/CUG200 cells (Fig. 5D) .
Lastly, we determined if Celf1 shRNA affected alternative splicing events in RNA toxicity myoblasts. Compared to normal myoblast differentiation (compare Supplemental Fig. S2 to Fig. 6 ), RNA toxicity resulted in altered splicing patterns. For instance, exon 11 of Zasp showed reduced inclusion in RNA toxicity myotubes (day 6 of differentiation). The exon 11 exclusion form of Bin1 showed increased expression in normal myotubes (day 6 of differentiation), but aberrantly more in RNA toxicity myoblasts (days 0-1). In the presence of Celf1 shRNA, the altered splicing patterns were not reversed (Fig. 6) . The alternative splicing dynamics were highly comparable during myoblast differentiation. These data support that blockage of Celf1 upregulation has little to do with alternative splicing regulation, which may explain the incomplete rescue of differentiation in RNA toxicity cells.
Discussion
It's well established that DMPK 3′-UTR CUG-expansion is responsible for myotonic dystrophy 1. CUG-expansion was known to inhibit terminal myocyte differentiation. Here, we show for the first time that CUGexpansion led to accelerated cell cycling which may partially explain the defective differentiation. Introduction of Celf1 shRNA into CUGexpansion cells partially rescued myocyte differentiation, by reversing the cell cycle exit deficiency at myoblast level.
During normal development, DMPK and Celf1 are regulated independently. While DMPK has a predominant expression in the muscles, Celf1 is largely enriched in the neuroectoderm derivatives [24, 25] . The expression patterns of Celf1 implies a non-obligatory role in muscle differentiation, which is supported by the lack of muscle phenotype in Celf1 knockout mice, such animals were chiefly defective in reproduction [26] . However, existing literature also indicates that Celf1 mediates key events in myocyte differentiation. Here, we have determined the function of Celf1 in normal myocyte differentiation using both loss and gain of function experiments. When Celf1Flag is expressed in C2C12 cells, it largely recapitulated the effect of CUG-expansion in inhibiting myotube formation. The stably transfected Celf1Falg was chiefly located in the nucleus, which is in line with previous reports that cytoplasm Celf1 positively regulates myotube formation. But, when endogenous Celf1 levels were knocked down by specific shRNAs, myotube formation was promoted, resulting in a precocious differentiation program. Our data herein support that in normal differentiation conditions, Celf1 plays an inhibitory role in myogenesis. Also, Celf1 appears to be a powerful regulator of cell cycle. Overexpression of Celf1 significantly increased the number of cycling cells in myoblasts and at the initiation stage of differentiation. This essentially recapitulates the cell cycle effect of CUG200, suggesting that Celf1 mediates the acceleration of cell cycling in RNA toxicity myoblasts. It was reported that the muscles from DM1 patients had increased satellite cell number but without proper terminal differentiation and muscle regeneration, especially in congenital cases [27, 28] . The effect of Celf1 on cell cycle control may explain such a baffling phenomenon, and supporting that Celf1 upregulation resulted from RNA toxicity may contribute to the pathogenesis of congenital DM1.
It was recently reported that dominant negative CELF1 protein rescued splicing defects in a cell culture system and a DM1 mouse model [29] . In this study, we have not observed significant changes in DM1-related alternative splicing events, when Celf1 was knockdown by shRNAs. During myocyte differentiation, some DM1-related alternative splicing events were dynamically regulated, but the presence of Celf1 shRNA did not alter the temporally regulated alternative splicing events. Thus, we conclude that alternative splicing defects were not a major factor in defective myocyte differentiation in DM1; instead, the cell cycle exit defect may play a predominant role. As additional support of this notion, a recent report of Celf1 knockout in the context of RNA toxicity did not find rescuing of defective alternative splicing: not only general targets like Clcn-1 and Tnnt3 but also reported CELF1-specific targets (Nrap and Fxr1h) remain misregulated by CUG-expanded RNA even in the absence of CELF1 [30] .
We also tried to answer if Celf1 upregulation is fully responsible for CUG-expansion-led inhibition of myocyte differentiation. In contrast to precocious myocyte differentiation resulted from Celf1 knockdown in wildtype myoblasts, only partial rescue of differentiation was achieved in cells with CUG-expansion. CUG-expansion-induced cell cycling was completely reversed by Celf1 knockdown. The rescue of cell cycle exit defect, however, did not make the cells to differentiate to the degree seen in wildtype cells. These data suggest that in myotonic dystrophy myoblasts, upregulation of Celf1 was only partially responsible for the defect in terminal differentiation. Additional pathological factors that resulted from CUG-expansion may also contribute to impaired differentiation. In a recent study where Celf1 deficiency was evaluated for correcting CUG-expansion RNA toxicity, the loss of CELF1 prevented deterioration of muscle function by the toxic RNA, and resulted in better muscle histopathology [30] . Together, these data support that reduced Celf1 levels in myoblasts may lead to better terminal skeletal muscle differentiation. Thus, Celf1 remains to be a valid target for DM1, especially in congenital DM1 treatment. The newly developed CRISPR/Cas9 technology offers an excellent tool to achieve it. This strategy is particularly attractive as low efficiency gene correction in satellite cells can lead to high phenotypic correction, as indicated in a recent report of Duchenne muscular dystrophy gene editing [31] . This strategy may be best employed in combination with other therapeutic strategies, such as targeting defective alternative splicing.
Methods
Cell culture and differentiation
C2C12 mouse myoblasts were propagated in Dulbecco's modified Eagle's medium, supplemented with 20% fetal bovine serum (FBS; Atlanta Biologicals), 100 U/ml penicillin G, 100 μg/ml streptomycin sulfate, and 2 mM L-glutamate. To induce myocyte differentiation and myotube formation, the cells were grown in DMEM containing 2% equine serum and 1 μM insulin (Sigma Aldrich). Samples were collected on a serial of time points, including days 0 (in propagating media), 2, 4, 6 and 8, except where otherwise specified, and were analyzed by immunostaining, realtime RT-PCR, and FACS. The medium was replaced every two days.
Vector construction and delivery
The GFP-CUG5 and GFP-CUG200 constructs were described previously [17, 30] . Maxipreps of these plasmids were transfected into C2C12 cells using Lipofectamine (Life Technologies). 2 days post-transfection, the cells were selected with G418 (1 mg/ml) for 10 days, and the resistant cells were analyzed in subsequent experiments as a pool.
pMSCV-Celf1Flag-Puro (thereafter referred to as Celf1Flag) was constructed by inserting an EcoRI fragment containing Celf1Flag from a donor plasmid pcDNA3-Celf1Flag (Tom Cooper, Baylor College of Medicine) into pMSCV-Puro (Clontech). Maxipreps of the resulting construct were used to prepare retroviral vectors using a packing cell line 293T Ecopack (Clontech). The retrovirus was next transduced into C2C12 cells. 3 days post-transduction, the cells were selected with puromycin (2 μg/ml) for 5 days. Resistant cells were analyzed as a pool in subsequent experiments.
pLKO.1 based Celf1 shRNA lentiviral vector was originally developed by The RNAi Consortium (GE Healthcare, clone ID TRCN0000098511). Scrambled control shRNA was obtained from the same source. For virus production, 20 μg of shRNA-encoding lentiviral vector was transfected along with 15 μg of packaging vector psPAX2 and 10 μg of envelope vector pMD2.G (gifts from Didier Trono, University of Geneva) into a 150 mm dish of 293T cells, using calcium phosphate. Culture supernatant containing lentiviral particles was collected 48 and 60 h after transfection and combined. The pooled supernatant was cleared of cell debris by centrifugation at 2000 rpm (1000 ×g) for 5 min. 0.5 ml of supernatant was used to infect a 60 mm dish of C2C12 culture, and resistant clones to puromycin (2 μg/ml) were pooled for subsequent analyzes.
Antibodies and immunoassays
For western blotting, cell lysates were size-fractionated by electrophoresis in 8% or 10% SDS-polyacrylamide gels and transferred to nitrocellulose membranes. Membranes were incubated in phosphate-buffered saline, 3% bovine serum albumin, and 0.05% Tween-20 (Bio-Rad), and then incubated overnight at 4°C with the primary antibodies: mouse monoclonal antibody to Celf1 (1:1000; Santa Cruz Biotechnology), mouse antibody to Flag (1:2000; Santa Cruz Biotechnology), and goat antibody to total actin (1:1000; Santa Cruz Biotechnology). The membranes were next incubated with horseradish peroxidase-conjugated secondary antibodies to the appropriate IgG: anti-goat (1:1000, Santa Cruz Biotechnology) and anti-mouse (1:2000, Pierce). Bound antibodies were visualized with enhanced chemiluminescence reagents (Amersham Biosciences).
For immunostaining, monolayer cultures were fixed in 4% paraformaldehyde in PBS for 10 min, followed by permeabilization in 0.1% Triton X-100 in PBS for 30 min at room temperature. The samples were next incubated in blocking buffer (0.1% Triton X-100, 10% normal goat serum in PBS) for 30 min at 37°. Primary antibody (MF-20, 1:100, Developmental Hybridoma Bank; Flag, 1:100, Santa Cruz) incubation in blocking buffer was carried out at 4°overnight. Secondary antibody (Texas red conjugated goat anti-mouse IgG, 1:500, Life Technologies) incubation in staining buffer (0.1% Tween-20 in PBS) was 1 h at room temperature. Finally, images were visualized and captured with a Nikon fluorescent microscope.
Realtime quantitative RT-PCR
Total RNA was extracted using TRIzol reagent (Invitrogen). RNA (100 ng) was subjected to quantitative RT-PCR using the Taqman One-Step RT-PCR Master Mix reagent (Applied Biosystems) and a 7700 Sequence Detector System (Applied Biosystems). Copy number for each transcript is calculated relative to that of glyceraldehyde-3-phosphate dehydrogenase (GAPDH), as a constitutive control. Sequences of primers and probes are as the following: GAPDH (forward, TGTGTCCGTCGTGGATCTGA; reverse, CCTGCTTCACCACCTTCTTGA; probe, CCGCCTGGAGAAACCTGCCAAGTATG), MyoD (forward, CTGATG GCATGATGGATTACAGC; reverse, GACACAGCCGCACTCTTCC; probe, CGGCGGCAGAATGGCTACGACACC), MyoG (forward, GAGAGAAAGATG GAGTCCAGAGAG; reverse, TCAGGAAGAGACTAGAACAGATGTG; probe, ACACTTGTCCAGGTCAGGGCACTCA), and Mef2c (forward, TCCACTCCCC CATTGGACT; reverse, TGCGCTTGACTGAAGGACTTT; probe, ACCAGACC TTCGCCGGACGAAAG).
Alternative splicing analyses by RT-PCR
Total RNA was extracted using TRIzol reagent (Invitrogen). cDNA was synthesized from 1 μg total RNA using the SuperScriptase III kit (Invitrogen), and then amplified using gene/exon specific primers [22, 23] : Zasp (forward, GGAAGATGAGGCTGATGAGTGG; reverse, TGCT GACAGTGGTAGTGCTCTTTC), MBNL1 (forward, GCTGCCCAATACCAGGTC AAC; reverse, TGGTGGGAGAAATGCTGTATGC), Z-TTN (forward, TGTTGC GACTGTCGTTGCTG; reverse, TCCACATGCGTAGGCTCTCTG), M-TTN (forward, GTGTGAGTCGCTCCAGAAACG; reverse, CCACCACAGGACCATGTT ATTTC), and BIN1 (forward, CACTATGAGTCTCTTCAAAC; reverse, GCAG ATCCACGTTCATCTCC). PCR products were separated on 1% agarose gels and the bands were quantified using the ImageJ software.
Fluorescence activated cell sorting
FACS was used to determine the cell cycle distribution of propagating and early stage differentiated myoblasts. Briefly, cells were harvested by trypsinization and washed in PBS. Next, the samples were fixed in cold 70% ethanol for 30 min at 4°. After washing with PBS twice, the samples were stained with propidium iodide (50 μg/ml in PBS containing 10 μg/ml RNase A) for 20 min at room temperature. FACS was performed on an Acuri C6 flow cytometer (Becton Dickinson), and the data were analyzed using Flowjo software with the Dean-Jett-Fox model (Tree Star).
Quantification of staining and statistical analyzes
The fusion index of the cultures was calculated by dividing the total number of nuclei in myotubes (≥2 nuclei) by the total number of nuclei counted. The total myotube area was calculated as the percentage of the total image area covered by myotubes. At least 1000 nuclei were counted in each analysis, which covered at least 3 randomly selected culture areas.
Analysis of data was performed by Student's T tests in order to evaluate differences between groups. p b 0.05 is considered significant.
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